<br>        Inclusion Criteria:<br><br>        Subjects may be enrolled in the study only if they meet all of the following criteria:<br><br>          1. Subject must be willing and able to sign informed consent<br><br>          2. Subject must have completed the 24-week double-blind Treatment Period in 1 of the 3<br>             core studies (CL04041022, CL04041023, or CL04041025).<br><br>          3. Subject must have maintained their stable dose (and route) of MTX 15 to 25 mg/week (or<br>             =10 mg/week if there is documented intolerance to higher doses) during the core study<br>             and plan to maintain the same dose and route of administration for additional 12 weeks<br><br>          4. Subjects must be willing to take folic acid or equivalent throughout the study.<br><br>        Exclusion Criteria:<br><br>          1. Subject with any medically important condition in the core study (e.g., clinically<br>             significant laboratory values, frequent AEs or SAEs, infection SAEs, and/or other<br>             concurrent severe and/or uncontrolled medical condition) which would make this subject<br>             unsuitable for inclusion in the open-label extension (OLE) study in the Investigator's<br>             judgement.<br><br>          2. Subject has evidence of active tuberculosis (TB)<br><br>          3. Subject has planned surgery during the first 12 weeks of the OLE<br><br>          4. Female subjects who are pregnant or who are planning to become pregnant during the<br>             study or within 6 months of the last dose of study drug<br><br>          5. Female subjects of childbearing who are not willing to use a highly effective method<br>             of contraception during the study OR Male subjects with partners of childbearing<br>             potential not willing to use a highly effective method of contraception during the<br>             study.<br><br>          6. Subject is unwilling or unable to follow the procedures outlined in the protocol<br><br>          7. Other medical or psychiatric conditions, or lab abnormalities that may increase the<br>             potential risk associated with study participation and administration of<br>             investigational medicinal products (IMPs), or that may affect study results<br>             interpretation and, as per Investigator's judgement, make the subject ineligible<br><br>        The following restrictions may affect a subject's ability to participate in this study:<br><br>          -  Availability to attend visits according to the protocol within the allowed window<br>             period<br><br>          -  Ability to perform self-administration of study drug and availability of caregiver to<br>             administer study drug<br><br>          -  Concomitant medication restrictions as described in the Informed Consent Form and<br>             protocol (water and concomitant medications are permitted) for at least 9 hours prior<br>             to all study visits 8. Subject with a positive or repeated indeterminate<br>             interferon-gamma release assay (IGRA) result at Week 22 of the core study<br><br>          -  Subjects may be enrolled in the OLE study if they fulfill all 3 of the following<br>             criteria prior to the first dose of study treatment:<br><br>               1. Active TB is ruled out by a certified TB specialist or pulmonologist who is<br>                  familiar with diagnosing and treating TB (as acceptable per local practice);<br><br>               2. The subject starts prophylaxis for LTBI according to country-specific/Centers for<br>                  Disease Control and Prevention (CDC) guidelines (see Appendix 4 [Section 13.4])<br>                  (treatment with isoniazid for 6 months is not an appropriate<br><br>        The Investigator (or designee) should review these restrictions with the subject during the<br>        Screening Period to determine any potential challenges in the subject's ability to comply<br>        with the protocol. Subjects not able to comply with the above mentioned restrictions should<br>        not be enrolled into the study.<br>